Cost-effectiveness analysis of prenatal diagnosis: Methodological issues and concerns

Gynecologic and Obstetric Investigation

Volumn 60, Issue 1, 2005, Pages 11-18

  Caughey, Aaron B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Gynecology and Reproductive Sciences   (United States)

Author keywords

Cost benefit analysis; Cost effectiveness analysis; Economics; Prenatal diagnosis

Indexed keywords

ALPHA THALASSEMIA; AMNIOCENTESIS; ANEUPLOIDY; BETA THALASSEMIA; CHORION VILLUS SAMPLING; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DIAGNOSTIC TEST; DOWN SYNDROME; FETUS ECHOGRAPHY; GENETIC DISORDER; HUMAN; LIFE EXPECTANCY; MONTE CARLO METHOD; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS;

COST-BENEFIT ANALYSIS; FEMALE; FETAL DISEASES; GENETIC DISEASES, INBORN; HUMANS; MASS SCREENING; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 23244454757     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083480     Document Type: Review

References (40)

1. Chernew ME, Hirth RA, Cutler DM: Increased spending on health care: How much can we afford? Health Aff 2003;22:15-25.
2. Heffler S, Smith S: Health spending projections for 2001-2011: The latest outlook. Health Aff 2002;21:207-218.
3. Weinstein MC, Stason WB: foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1979;296:716-721.
4. Eisenberg JM: Clinical economics: A guide to the economic analysis of clinical practices. JAMA 1989;262:2879-2886.
5. Cutler DM, McClellan M: Is technological change in medicine worth it? Health Aff 2001;20:11-29.
6. Shackley P: Economic evaluation of prenatal diagnosis: A methodological review. Prenat Diagn 1996;16:389-395.
7. Gold MR, Siegal JE, Russell LB, Weinstein MC: Cost-effectiveness in health and medicine. New York, Oxford University Press, 1996.
8. Torrance GW: Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30.
9. Torrance GW, Thomas WH. Sacket DL: A utility maximization model for evaluation of health care programs. Health Serv Res 1972;7:118-133.
10. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB: Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-1258.
11. Detsky AS, Naglie IG: A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990;113:147-154.
12. Drummond MF, Jefferson TO: Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. Br Med J 1996;313:275-283.
13. Subak LL, Caughey AB, Washington AE: Cost-effectiveness analyses in obstetrics & gynecology. Evaluation of methodologic quality and trends. J Reprod Med 2002;47:631-639.
14. Smith WJ, Blackmore CC: Economic analyses in obstetrics and gynecology: A methodologic evaluation of the literature. Obstet Gynecol 1998;91:472-478.
15. Layde PM, von Allmen SD, Oakley GP Jr: Maternal serum alpha-fetoprotein screening: A cost-benefit analysis. Am J Public Health 1979;69:566-573.
16. Harris RA, Washington AE, Nease RF Jr, Kuppermann M: Cost utility of prenatal diagnosis and the risk-based threshold. Lancet 2004;363:276-282.
17. Steele MW, Breg WR Jr: Chromosome analysis of human amniotic fluid cells. Lancet 1966;1:383-385.
18. Kuppermann M, Goldberg JD, Nease RF Jr, Washington AE: Who should be offered prenatal diagnosis? The 35-year-old question. Am J Public Health 1999;89:160-163.
19. National Institute of Child Health and Human Development: Antenatal diagnosis: Report of a Consensus Development Conference. US Dept of Health, Education and Welfare, Public Health Service, National Institutes of Health, 1979.
20. Hagard S, Carter FA: Preventing the birth of infants with Down's syndrome: A cost-benefit analysis. Br Med J 1976;1:753-756.
21. Wapner R, Thom E, Simpson JL, et al: First-trimester screening for trisomies 21 and 18. N Engl J Med 2003;349:1405-1413.
22. Biggio JR Jr, Morris TC, Owen J, Stringer JS: An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. Am J Obstet Gynecol 2004;190: 721-729.
23. Caughey AB, Kuppermann M, Norton ME, Washington AE: Nuchal translucency and first trimester biochemical markers for Down syndrome screening: A cost-effectiveness analysis. Am J Obstet Gynecol 2002;187:1239-1245.
24. Brock DJ, Sutcliffe RG: Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida. Lancet 1972;2:197-199.
25. Chamberlain J: Human benefits and costs of a national screening programme for neural-tube defects. Lancet 1978;2:1293-1296.
26. Hagard S, Carter F, Milne RG: Screening for spina bifida cystica. A cost-benefit analysis. Br J Prev Soc Med 1976;30:40-53.
27. Nadel AS, Norton ME, Wilkins-Haug L: Cost-effectiveness of strategies used in the evaluation of pregnancies complicated by elevated maternal serum alpha-fetoprotein levels. Obstet Gynecol 1997;89:660-665.
28. Vintzileos AM, Ananth CV, Fisher AJ, Smulian JC, Day-Salvatore D, Beazoglou T, Knuppel RA: Cost-benefit analysis of targeted ultrasonography for prenatal detection of spina bifida in patients with an elevated concentration of second-trimester maternal serum alpha-fetoprotein. Am J Obstet Gynecol 1999;180:1227-1233.
29. Rary JM, Park IJ, Heller RH, Jones HW Jr, Baramki TA: Prenatal cytogenetic analysis of women with high risk for genetic disorders. J Hered 1974;65:209-212.
30. Kan YW, Dozy AM, Alter BP, Frigoletto FD, Nathan DG: Detection of the sickle gene in the human fetus. Potential for intrauterine diagnosis of sickle-cell anemia. N Engl J Med 1972;287:1-5.
31. Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C: Screening for sickle cell disease and thalassaemia: A systematic review with supplementary research. Health Technol Assess 2000;4:1-99.
32. Genetic testing for cystic fibrosis: NIH consensus statement 1997;15:1-37.
33. Lieu TA, Watson SE, Washington AE: The cost-effectiveness of prenatal carrier screening for cystic fibrosis. Obstet Gynecol 1994;84:903-912.
34. Cuckle HS, Richardson GA, Sheldon TA, Quirke P: Cost effectiveness of antenatal screening for cystic fibrosis. Br Med J 1995;311:1460-1463.
35. Rowley PT, Loader S, Kaplan RM: Prenatal screening for cystic fibrosis carriers: An economic evaluation. Am J Hum Genet 1998;63:1160-1174.
36. Wildhagen MF, Hilderink HB, Verzijl JG, Verheij JB, Kooij L, Tijmstra T, ten Kate LP, Habbema JD: Costs, effects, and savings of screening for cystic fibrosis gene carriers. J Epidemiol Community Health 1998;52:459-467.
37. Vintzileos AM, Ananth CV, Smulian JC, Fisher AJ, Day-Salvatore D, Beazoglou T: A cost-effectiveness analysis of prenatal carrier screening for cystic fibrosis. Obstet Gynecol 1998;91:529-534.
38. Doyle NM, Gardner MO: Prenatal cystic fibrosis screening in Mexican Americans: An economic analysis. Am J Obstet Gynecol 2003;189:769-774.
39. Vintzileos AM, Ananth CV, Fisher AJ, Smulian JC, Day-Salvatore D, Beazoglou T, Knuppel RA: Economic evaluation of prenatal carrier screening for fragile X syndrome. J Matern Fetal Med 1999;8:168-172.
40. Musci TJ, Caughey AB: Cost-effectiveness analysis of prenatal population-based fragile X carrier screening. Am J Obstet Gynecol 2004;189:S117.